In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Thermo Fisher acquires CDMO Patheon in megadeal valued at nearly $7.2bn

29 Aug 2017

Executive Summary

Drug development/delivery company Thermo Fisher Scientific Inc. acquired leading contract development and manufacturer Patheon NV for $35 per share (31% premium to prior 10 day trading average) or nearly $7.2bn in enterprise value (including $2bn in net debt).
Deal Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By